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Abstract
Glufosfamide is an alkylating agent consisting of
iphosphoramide mustard conjugated to glucose that is
currently included in clinical studies of pancreatic can-
cer. We studied the effects of glufosfamide, in combi-
nation with gemcitabine, on in vitro and in vivo models
of pancreatic cancer. In proliferation assays, glufosfa-
mide and gemcitabine inhibited the growth of MiaPaCa- 2,
H766t, and PANC-1 cells, but the combination of the two
agents provided greater effects. Apoptosis of MiaPaCa-2
cells, measured by fluorescence-activated cell sorting,
was enhanced by the combination of the two drugs,
compared to single-agent treatment. Glufosfamide
alone inhibited the growth of red fluorescent protein–
expressing MiaPaCa-2 tumors in an orthotopic nude
mouse model in a dose-dependent manner. Combining
glufosfamide (30 mg/kg) with gemcitabine resulted in
enhanced inhibition of tumor growth and significantly
prolonged survival. Immunohistochemistry of excised
tumors revealed that both glufosfamide and gemcita-
bine increased levels of apoptosis (measured by termi-
nal deoxynucleotidyl transferase–mediated nick end
labeling staining) and reduced proliferation (measured
by proliferating cell nuclear antigen staining). No ef-
fects on microvessel density were observed. These re-
sults support the use of the alkylating agent glufosfamide
and the DNA synthesis inhibitor gemcitabine, rather
than the use of either agent alone, to provide greater
benefits and demonstrate that this combination treat-
ment should be useful in the clinical treatment of pan-
creatic carcinoma.
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Introduction
Adenocarcinoma of the ductal pancreas is characterized
by extensive local invasion and early metastasis. In most
patients, the disease, when detected, is usually already well
developed locally or has already metastasized [1,2]. Thus,
the 5-year survival rate of these patients is only 3% to 4%
[3], with a median survival after diagnosis of approximately
6 months [4]. Gemcitabine, a deoxycytidine analogue, has a
moderately extended median survival for patients with ad-
vanced pancreatic cancer [5,6] and is currently the standard
of care as first-line therapy. Gemcitabine induces apoptosis of
human pancreatic cancer cells and can inhibit tumor growth
and progression [7]. In addition, intracellular phosphorylation of
gemcitabine produces diphosphate and triphosphate molecular
forms capable of acting as fraudulent bases in DNA and also
capable of inhibiting DNA synthesis–dependent ribonucleotide
reductase [8], together producing a strong cytotoxic effect. A
recent study has suggested that gemcitabine may be more
effective as adjuvant therapy after complete surgical resection
of pancreatic cancer and may increase survival by as much
as 6 months in these patients receiving surgery [9]. Even so,
the moderate therapeutic advantage of gemcitabine therapy
over best supportive care, either as primary care or in the
adjuvant setting, indicates that there is a need for new treat-
ment strategies for pancreatic cancer. Among the promising
agents currently under investigation for first-line and second-
line therapies for the treatment of pancreatic carcinoma is
glufosfamide, a glucose-coupled iphosphoramide mustard with
alkylating properties. Glufosfamide was developed to avoid
the need for the activation of ifosfamide by P450 in the liver,
thus reducing toxicities associated with systemic exposure to
multiple metabolites of ifosfamide, including acrolein [10]. The
glucose moiety may allow enhanced uptake by tumor cells
because of upregulated sodium transporters [11]. One potential
glucose transport mechanism has been implicated [12], al-
though others have not been ruled out. In tumor cells, glufos-
famide is cleaved by glucosidases to liberate the cytostatic
agent iphosphoramide mustard [13]. Glufosfamide exhibits
lower myelotoxicity and increased antitumor activity in preclin-
ical in vitro and in vivo studies [14]. Here we present data that
specifically address the likelihood that glufosfamide and gem-
citabine may have benefits as combination therapy. Data
on this particular combination treatment have not been previ-
ously reported, and the results support the use of these two
agents to provide at least additive effects on models of human
pancreatic cancer.
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Methods
Cell Lines and Reagents
MiaPaCa-2, AsPC-1, H766t, and PANC-1 cell lines were
obtained from the American Type Culture Collection (Rock-
ville, MD). All cell lines were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum,
sodium pyruvate, nonessential amino acids, L-glutamine,
vitamins, and antibiotics. Cells were maintained in a humid-
ified incubator containing 10% CO2 at 37jC. All chemical
reagents were purchased from Sigma Chemical Co. (St.
Louis, MO), unless otherwise specified. Gemcitabine was
purchased from Eli Lilly Co. (Indianapolis, IN), reconstituted
in sterile phosphate-buffered saline (PBS), and stored at room
temperature for in vivo studies or in aliquots at 20jC for in vitro
studies. Glufosfamide was provided directly by Threshold
Pharmaceuticals, Inc. (Redwood City, CA), and freshly recon-
stituted in PBS for each study. Anti–proliferating cell nuclear
antigen (PCNA) and anti-CD31 monoclonal antibodies were
obtained from Dakocytomation Corp. (Carpinteria, CA).
Cell Proliferation Assay
Cells were collected from exponentially growing cultures.
Cell numbers were determined by direct counting with a
hemocytometer, and cell viability was determined by trypan
blue exclusion. For cell growth curves, 1  106 cells were
plated in triplicate for each dose level. After 24 hours, the
culture medium was removed and replaced with a fresh
medium mixed with 1 mg/ml gemcitabine, 10 mg/ml glufosfa-
mide, or both. These concentrations were selected based on
preliminary studies and represent approximately 50% inhib-
itory concentrations. Cells were counted with a hemocytom-
eter every 24 hours for 3 days. Each experiment was
conducted on three separate occasions.
Determination of DNA Fragmentation By
Fluorescence-Activated Cell Sorting
(FACS) Analysis
Cells (1  106) were incubated with vehicle, gemcitabine,
glufosfamide, or a combination of both agents at 10 mg/ml for
24 hours. The cells were then collected by gentle trypsiniza-
tion, washed with PBS, and pelleted by centrifugation. Cells
were resuspended in PBS containing 50 mg/ml propidium
iodide (PI), 0.1% Triton X-100, and 0.1% sodium citrate. The
samples were then stored at 4jC for 16 hours and vortex-
mixed before FACS analysis. The relative percentage of cells
in the sub-G1 region was then quantitated and used as an
estimate of cells undergoing apoptosis. FACS channels were
set based on reference analysis and maintained constant
during the experiments.
Orthotopic Mouse Model of Pancreatic Cancer
Orthotopic tumors were generated using MiaPaCa-2 cells
that had been transfected to stably express red fluores-
cent protein (RFP), as previously described [15]. Tumor
stocks were made by subcutaneously injecting MiaPaCa-
2–RFP cells, at a concentration of 5  106 cells per 200 ml,
into the flanks of nude mice. Tumor tissues were resected
aseptically, and any grossly necrotic or suspected necrotic
or non-RFP tumor tissues were removed. The remaining
healthy tumor tissues were subsequently cut into small frag-
ments of approximately 1 mm3. Recipient mice were anes-
thetized with isoflurane, and the surgical area was sterilized
using iodine and alcohol. An incision approximately 1.5 cm
long was made on the left upper abdomen of nude mice
using a pair of surgical scissors. The pancreas was ex-
posed, and then two pieces of MiaPaCa-2–RFP tumor frag-
ments (in mm3) were transplanted to the mouse pancreas
with 8-0 surgical sutures (nylon) after the capsule of the
transplantation site had been stripped. The abdomen was
closed with 6-0 surgical sutures (silk). All procedures of
the operation described above were performed with a 7
magnification microscope (Olympus, Center Valley, PA) under
high-efficiency particulate-arresting filter laminar flow hoods.
During the course of the study, the primary tumor size
for each animal was followed on a weekly basis. Primary
tumor sizes were estimated by measuring perpendicular
minor dimension (W ) and major dimension (L) using sliding
calipers. Approximate tumor volume was calculated by the
formula: W 2L  1/2. At the end of the study, the primary
tumor burden was verified, and metastasis was evaluated
by whole-body imaging as previously described [15,16].
Briefly, the mice were placed in a fluorescent light box
equipped with a fiber-optic light source of 490 nm (Lightools
Research, Encinitas, CA). Selective excitation of RFP was
produced through aD425/60 bandpass filter and a 470DCXR
dichroic mirror. Emitted fluorescence was collected through a
longpass filter GG475 (Chroma Technology, Brattleboro, VT)
on a Hamamatsu C5810 3 chip-cooled color charge-coupled
device camera (Hamamatsu Photonics, Bridgewater, NJ).
Images were processed for contrast and brightness, and
analyzed with the use of Image Pro Plus 3.1 software (Media
Cybernetics, Silver Spring, MD). High-resolution images of
1024  724 pixels were captured directly on an IBM PC (IBM,
Armonk, NY) or continuously through video output on a high-
resolution Sony VCR (model SLV-R1000; Sony, Tokyo, Japan).
To evaluate the efficacy of glufosfamide alone in this
model and to determine the optimal dosage for combination
experiments, an initial experiment, in which groups of
six mice were randomized into one of several groups when
tumors had reached 100 to 150 mm3, was conducted.
Glufosfamide was administered intravenously, in doses of 3
to 100 mg/kg per day, for 14 days. Saline was administered
to control mice. Based on the results of this study, doses of
10 and 30mg/kg per day were selected for a second study. In
the second study, groups of 10 mice were treated with
glufosfamide alone, intravenously, daily for 14 days; with
gemcitabine alone, intraperitoneally, at 300 mg/kg once a
week for 3 weeks; or in combination. Based on the obser-
vations of animals in this study and in general pharmacology
studies previously reported [17], this dose of gemcitabine,
although higher than used in some studies, was considered
safe. However, to be sure, we have conducted a study in
which nude mice were injected once a week for 3 weeks and
detected no changes in liver or renal enzymes. Saline-
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treated mice served as controls. As before, treatment
was initiated when tumors had reached 100 to 150 mm3.
The metastatic frequency of all groups was analyzed with
Fisher’s exact test. Differences in animal survival time be-
tween each treatment group and control were compared
with log-rank analysis. Tumor sizes at 14 and 21 days were
compared using Kruskal-Wallis test followed by log-rank
analysis. All values were considered significant at P < .05.
Immunohistochemistry of Pancreatic Tumors
In a separate experiment, tumors were established in
groups of five nude mice by an intrapancreatic injection of
1  106 MiaPaCa-2 cells after a midline incision and lapa-
rotomy under isoflurane anesthesia and aseptic conditions.
When tumor size was approximately 150 mm3, treatment
was initiated with 30 mg/kg per day of glufosfamide, intrave-
nously, for 14 days; with 300 mg/kg per day of gemcitabine,
intraperitoneally, once a week for 2 weeks (days 1 and 8 of
treatment); or with both agents. PBS served as vehicle
control. One day after the final glufosfamide dose, tumors
were harvested and frozen until analyzed.
Frozen tissue sections were fixed, and 5-mm sections
embedded in paraffin were prepared for terminal deoxynu-
cleotidyl transferase–mediated nick end labeling (TUNEL)
assay using a commercial kit (Promega, Madison, WI) ac-
cording to the manufacturer’s instructions. Background re-
activity was determined by processing slides in the absence
of terminal deoxynucleotidyl transferase (negative control).
Nuclei were stained with PI (1 mg/ml) for 10 minutes. Fluo-
rescent bleaching was minimized with an enhancing reagent
(Prolong; Molecular Probes, Eugene, OR). Immunofluores-
cence microscopy was performed with a fluorescent mi-
croscope equipped with narrow bandpass excitation filters.
Images were captured using a Nikon camera (Photometrics,
Tucson, AZ). DNA fragmentation was detected by local-
ized green fluorescence within the nucleus of apoptotic
cells. For quantification of total TUNEL expression, the num-
ber of apoptotic events was counted in 10 random fields at
100 magnification.
For the detection of PCNA and CD31 by immunohisto-
chemistry, paraffin-embedded tissues were mounted on
positively charged Superfrost slides (Fisher Scientific, Hous-
ton, TX) and dried overnight. Sections were deparaffinized in
xylene, treated with a graded series of alcohol (100%, 95%,
and 80% ethanol/double-distilled H2O, vol/vol), and rehy-
drated in PBS (pH 7.5). To enhance antigen retrieval, sec-
tions were microwaved for 5 minutes. For detection of CD31,
paraffin-embedded tissues were treated with pepsin (Bio-
meda, Foster City, CA) for 15 minutes at 37jC and washed
with PBS. After exposure to anti-PCNA or anti-CD31 anti-
bodies followed by washing with PBS, positive reactions
were visualized by incubating the slides with stable 3,3-
diaminobenzidine for 10 to 20 minutes. The sections were
rinsed with distilled water, counterstained with Gill’s hema-
toxylin for 30 seconds, and mounted with Universal Mount
(Research Genetics, Carlsbad, CA). Control samples ex-
posed to secondary antibody alone showed no specific
staining. For quantification of microvessel density (MVD),
10 randomly selected fields at 100 magnification were
captured for each tumor, and microvessels were quantified
according to the method described previously [26,27].
For quantification of PCNA expression, the number of pos-
itive cells was quantified in 10 randomly selected fields
at 100 magnification.
Figure 1. Effects of glufosfamide and gemcitabine on proliferation assays.
MiaPaCa-2 (A), H766t (B), and AsPC-1 (C) pancreatic cells were grown
in culture media for 3 days, as described in Methods. Glufosfamide and
gemcitabine were added to the media at the indicated concentrations alone or
together, and cell numbers were determined daily with a hemocytometer.
Each experiment was conducted in triplicate. **P < .01 vs gemcitabine alone.
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Results
Proliferation Assay
Based on preliminary experiments, a gemcitabine con-
centration of 1 mg/ml was selected to examine its growth-
inhibitory effects. Three separate experiments, in which
gemcitabine strongly inhibited the growth of MiaPaCa-2,
H766t, and PANC-1 cells and exhibited moderate effects on
the growth of AsPC-1 cells, were conducted (Figure 1).
Glufosfamide at 10 mg/ml was less effective than gemcitabine.
However, when glufosfamide was added to gemcitabine, ad-
ditional inhibition of the cell growth of MiaPaCa-2, PANC-1,
and H766t cells, but not of AsPC-1 cells, was observed.
DNA Fragmentation
Because cytotoxicity assay indicated that glufosfamide
and gemcitabine, either alone or in combination, were most
effective against MiaPaCa-2 cells, FACS analysis of the DNA
fragmentation of MiaPaCa-2 cells was conducted to deter-
mine whether apoptosis was induced by this combination.
Treatment of MiaPaCa-2 cells with 10 mg/ml glufosfamide or
1 mg/ml gemcitabine resulted in induction of apoptosis as
measured by an increase in apoptosis (sub-G1 fraction;
Figure 2), although the effect of gemcitabine was greater.
Treatment with both agents resulted in enhanced apoptosis
that was slightly greater than additive.
Orthotopic Model of Pancreatic Cancer
In a preliminary study, the activity of glufosfamide was
evaluated in the MiaPaCa-2–RFP model to determine the
best doses to be used in combination with gemcitabine.
Figure 3A shows final tumor volumes recorded at necropsy,
for glufosfamide at 3 to 100mg/kg, intravenously, for 14 days,
and gemcitabine at 300 mg/kg, intraperitoneally, once a
week for 3 weeks. Treatment was initiated when tumors
had reached 100 to 150 mm3. Glufosfamide treatment re-
sulted in dose-related reductions in tumor volume; a dose of
100 mg/kg was similar in effect to gemcitabine. In addition, at
Figure 2. Analysis of DNA fragmentation by FACS. Cells (1  106) were incubated with vehicle (A), gemcitabine (B), glufosfamide (C), or the combination of both
agents (D) at 10 g/ml for 24 hours, with the addition of PI. DNA fragmentation (apoptosis) is indicated by events in Sub-G1 Phase.
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doses of 30 mg/kg or higher, there was an significant in-
crease in the time to 50% survival—an effect not significantly
different from gemcitabine (Figure 3B).
To evaluate combination therapy in the samemodel, doses
of 10 and 30 mg/kg glufosfamide were chosen to be tested
with and without 300 mg/kg gemcitabine. Figure 4A shows
the weekly primary tumor volumes for each group. Because
significant numbers of deaths were observed in three of the
groups (vehicle, 10 mg/kg glufosfamide, and 30 mg/kg glu-
fosfamide) after day 26, statistical evaluation was restricted to
the initial 26-day period. On day 26, 14 days after initiation
of treatment, glufosfamide at 10 mg/kg alone was without
effect, whereas 30 mg/kg significantly reduced tumor size by
approximately 50%. The effect of gemcitabine was somewhat
greater than that of glufosfamide. However, combining 30 mg/
kg glufosfamide with gemcitabine resulted in a significant
increase above the level achieved by gemcitabine alone.
Figure 5 shows images obtained from representative animals
from the vehicle, gemcitabine, and combination groups. RFP
expression was evident in the pancreas but was also seen
to have spread to the abdominal lymph nodes of all control
mice and to the diaphragm of a few mice (Table 1). Treatment
with glufosfamide or gemcitabine reduced RFP expression
in the primary tumor and also reduced the incidence of
metastasis. The magnitude of the inhibition of metastatic inci-
dence was similar among treatments, except for the 10-mg/kg-
glufosfamide group, which was ineffective under the conditions
of this study (Table 2). Figure 4B shows the survival curves
for each group and indicates that only the combination of
30mg/kg glufosfamide and gemcitabine significantly increased
survival relative to control. Treatment with either agent alone or
with both agents had no effect on body weights in this study
(data not shown).
Immunohistochemistry of Pancreatic Tumors
Figure 6 shows the apoptotic and proliferative indexes
derived from TUNEL-stained and PCNA-stained sections of
tumors from mice treated with saline, glufosfamide (30 mg/kg,
iv, daily for 2 weeks), with gemcitabine (300 mg/kg, once a
week for 2 weeks), or with both agents in combination. Tumors
were removed 24 hours after the last treatment (at 2 weeks)
and then weighed. Similar to the RFPmodel described above,
treatment with gemcitabine alone yielded a reduction in tumor
weight from 2.2 ± 0.5 to 1.4 ± 0.5 g. Glufosfamide at 10 mg/kg
decreased only to 1.9 ± 0.6 g, whereas 30mg/kg glufosfamide
reducedweight to 1.6 ± 0.4 g. Again, combination therapy was
most effective. Although the addition of 10mg/kg glufosfamide
to gemcitabine added little effect, combination with gemcita-
bine and 30 mg/kg reduced weight to 0.9 ± 0.3 g, a significant
effect. In these tumors, apoptosis occurred at a low level in
control mice, but was significantly increased by glufosfamide
and, to a greater degree, by gemcitabine (Figure 6). Combi-
nation treatment resulted in a level of apoptosis that was
significantly greater than that of either agent alone. PCNA
staining was significantly greater with both gemcitabine alone
and glufosfamide alone compared to control, indicating sig-
nificant antiproliferative effects. Combination treatment re-
sulted in significantly greater PCNA staining compared to
either treatment alone. CD31 staining failed to reveal any ef-
fects of either treatment alone or combination treatment (data
not shown).
Discussion
This study was conducted to provide information on the
potential value of the use of glufosfamide in combination
with gemcitabine in the treatment of pancreatic cancer.
Although gemcitabine is considered the standard of care
as first-line treatment for pancreatic cancer [18], the benefit
of such treatment is limited and, thus, alternative or addi-
tional treatments are needed. Among alternative agents of
interest, glufosfamide, an alkylating agent in which the
alkylating metabolite of ifosfamide is linked to b-D-glucose,
has been studied in phase I and phase II trials. Part of the
rationale for the potential advantage of glufosfamide over
ifosfamide was that the active compound of ifosfamide,
iphosphoramide mustard, must be released from the parent
compound by liver microsomal enzymes [10]. In addition,
other toxic metabolites (such as acrolein), which are both
nephrotoxic and urotoxic, are released [19,20]. By coupling
iphosphoramide mustard to glucose, in theory, metabolic
activation should be avoided, toxic metabolites should be
Figure 3. Final tumor volumes (A) and 50% survival (B) recorded in the
MiaPaCa-2–RFP pancreatic cancer model. Glufosfamide was administered
intravenously daily for 14 days. *P < .05 vs control.
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limited, and the active compound should be taken up pref-
erentially by cells with upregulated sugar transporters and
then released by hydrolysis by intracellular glucosidases.
Thus, glufosfamide may take advantage of the observation
of the overexpression of glucose transporters by pancreatic
carcinomas [11].
Although several small clinical studies [21,22] have indi-
cated that glufosfamide had an activity similar to that indi-
cated by published results for gemcitabine, preclinical
studies such as those described here showing that glufosfa-
mide could be used in combination with gemcitabine to
provide even greater benefits have not been previously
reported. Our results clearly demonstrate that, at a minimum,
an additive benefit is associated with a combination treat-
ment with these two agents. In vitro proliferation and apop-
tosis assays indicated that addition of glufosfamide to
gemcitabine enhanced activity. Glufosfamide demonstrated
dose-dependent inhibition in the pancreatic orthotopic xeno-
graft model and enhanced the activity of gemcitabine. This
model takes advantage of a fluorescent biomarker (RFP) to
follow the disease in real time to more accurately follow the
effect of therapeutics on the particularly malignant human
cancer than can be conducted with traditional flank xenograft
models [15]. In this invasive lethal model, only the combina-
tion of 30 mg/kg glufosfamide and gemcitabine resulted in
a significant increase in survival. This finding is somewhat
surprising because treatment with glufosfamide alone or
gemcitabine alone in the preliminary study resulted in an
increase in 50% survival. However, examination of the
control groups in the two studies revealed that control tumors
grew much faster and that greater lethality was observed in
the second study. Thus, we conclude that single-agent
Figure 4. Primary tumor volumes (A) and survival curves (B) recorded in the MiaPaCa-2–RFP pancreatic cancer model. Gemcitabine (intraperitoneally, once a
week for 3 weeks) and glufosfamide (intravenously, daily for 14 days) each significantly reduced tumor volume measured on day 26, but the combination of 30 mg/kg
and gemcitabine resulted in significantly greater reduction. The same combination of treatments also provided significant improvement in survival. *P < .05.
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therapy in the second study was inadequate to affect these
more rapidly growing tumors significantly and that combina-
tion therapy was required to increase survival significantly.
Immunohistochemistry assay of apoptosis and proliferation
in treated tumors confirmed the additive effects of combina-
tion therapy on tumor size and indicated that both activities
are involved in the antitumor effects of both agents.
It is generally believed that chemotherapy and radiation
therapy exert their effects by apoptosis [23]. We investi-
gated apoptosis in our experiments and found that gemcita-
bine and glufosfamide both exhibited proapoptotic effects.
Bold et al. [24] concluded that Bcl-2 plays a major role in the
apoptosis evoked by gemcitabine because increased levels
of Bcl-2 correlated with resistance to gemcitabine in various
pancreatic cell lines. Interestingly, MiaPaCa-2 cells were
most sensitive to gemcitabine and were associated with
relatively low levels of Bcl-2 expression. This finding may,
in part, explain the high sensitivity of our MiaPaCa-2 tumors
to gemcitabine. Similarly, glufosfamide was found to induce
apoptosis in association with a decline in Bcl-2 levels [25],
and overexpression of Bcl-2 reduced the cytotoxic effect of
glufosfamide. Thus, gemcitabine and glufosfamide may
have some proapoptotic mechanisms in common. However,
other mediators of gemcitabine-mediated apoptosis have
been described [26,27], and the precise series of events
leading to glufosfamide cell death has not been well studied.
Although glufosfamide and gemcitabine may share some
activities, these agents should initiate cell death by different
mechanisms. Glufosfamide is hydrolyzed to iphosphoramide
mustard in tumor cells and acts as an alkylating agent lead-
ing to DNA double-stranded breaks [25,28]. In contrast,
gemcitabine is a deoxycytidine analogue that, after intracel-
lular phosphorylation to diphosphate and triphosphate mo-
lecular forms, inhibits ribonucleotide reductase, resulting in a
reduction in deoxynucleotide concentrations, including
dCTP. In addition, metabolites of gemcitabine compete with
dCTP for incorporation into DNA. These two mechanisms of
action lead to inhibition of DNA synthesis. Recently, an
additional activity of gemcitabine, which in our opinion could
explain the additional benefit derived from glufosfamide
treatment above that achieved with gemcitabine only in our
experiments, has been described. Gemcitabine was shown
Figure 5. Representative open-body images of individual mice from each treatment group. (A) Saline treatment. (B) Glufosfamide treatment. (C) Gemcitabine treat-
ment. (D) Glufosfamide + gemcitabine. White arrows, primary tumor; yellow arrows, abdominal lymph node metastases; green arrow, diaphragmatic metastases.
Table 1. Incidence of Metastasis to the Lymph Nodes and Diaphragm.
Groups Dose (mg/kg) Abdominal Lymph Nodes DiaphragmAvailable Tested
Animals (n)
Total Metastatic Incidence
(All Organs)
Metastatic Incidence P Metastatic Incidence P
Control – 9 10 9 – 1 –
Glufosfamide 10 10 9 8 .474 1 1.000
Glufosfamide 30 9 6 4 .029 2 1.000
Gemcitabine 300 9 4 3 .009 1 1.000
Glufosfamide + gemcitabine 10 + 300 8 1 1 .000 0 1.000
Glufosfamide + gemcitabine 30 + 300 10 2 2 .001 0 .474
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to inhibit homologous recombination mechanisms that are
required to repair double-stranded DNA breaks induced by
ionizing radiation or chemotherapy [29]. Becker et al. [25]
demonstrated that glufosfamide does induce DNA double-
stranded breaks. Therefore, it is reasonable to hypothesize
that, in the present experiments, gemcitabine may have
inhibited the repair of these lesions. Further experiments
are required to prove that this mechanism is the primary
explanation for our results.
In summary, these in vitro and in vivo studies have dem-
onstrated that glufosfamide enhances the effects of gemcita-
bine on multiple in vitro and in vivo models of pancreatic
cancer. The additional benefits appear to be, at least in part,
related to enhanced apoptosis and antiproliferation. These re-
sults suggest that glufosfamide could be useful as adjunctive
therapy in the treatment of patients with pancreatic cancer.
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